Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of aminooxyacetic acid (AOAA) in preparation of drug for preventing or treating myocardial infarction

A technology of aminooxyacetic acid and drugs, applied in drug combinations, pharmaceutical formulations, cardiovascular system diseases, etc., can solve problems that are difficult to be widely used, irreversible damage to heart tissue, and no research reports on aminooxyacetic acid myocardial infarction have yet been seen.

Pending Publication Date: 2020-01-10
SUZHOU UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Most of the current drug or device treatments can only relieve symptoms, but cannot reverse the damage to heart tissue
Although heart transplantation can completely improve the condition of the heart, it is difficult to be widely used clinically due to factors such as scarcity of donor sources, immune rejection, and expensive treatment costs.
At present, there are research reports on the application of aminooxyacetic acid (AOAA) in the preparation of drugs for the treatment of hepatocellular carcinoma, but so far there has been no research report on aminooxyacetic acid in the treatment of myocardial infarction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of aminooxyacetic acid (AOAA) in preparation of drug for preventing or treating myocardial infarction
  • Application of aminooxyacetic acid (AOAA) in preparation of drug for preventing or treating myocardial infarction
  • Application of aminooxyacetic acid (AOAA) in preparation of drug for preventing or treating myocardial infarction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Example 1: AOAA effectively improves cardiac function after myocardial infarction

[0019] Cardiac function after myocardial infarction detected by echocardiography

[0020] Mice were anesthetized (the same method as before), placed in the left lateral position after depilation, placed the probe of the cardiac ultrasound diagnostic instrument on the anterior wall of the heart, and took a two-dimensional short-axis view of the left ventricle at the level of the papillary muscle, and recorded M-scan at the same time, for 3 consecutive Cardiac cycle measurement left ventricular ejection fraction (EF), fractional shortening (FS) and left ventricular end diastolic diameter (LVEDD) and left ventricular end systolic diameter (LVESD).

[0021] Experimental results: Cardiac function was detected 28 days after myocardial infarction, and AOAA significantly improved cardiac function after myocardial infarction ( figure 1 ), ejection fraction ( figure 2 ) and short axis shortenin...

Embodiment 2

[0022] Example 2: AOAA effectively reduces the size of myocardial infarction

[0023] Masson staining: the mice were sacrificed 28 days after the operation, and the left ventricle tissue was taken for heart tissue staining to observe the therapeutic effect. Follow the routine Masson staining procedure, observe and take pictures under an ordinary light microscope. The image analysis software Image J was used to analyze the area of ​​each part, and the area of ​​myocardial infarction / heart area was calculated;

[0024] Experimental results: Masson staining was used to observe the infarct area of ​​each group 28 days after myocardial infarction ( Figure 4 & 5), AOAA was found to effectively reduce the size of myocardial infarction; *P < 0.05.

[0025] 【in conclusion】

[0026] The above results comprehensively prove that: AOAA can effectively improve the cardiac function after myocardial infarction, effectively reduce the size of myocardial infarction, so as to prevent or tre...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of aminooxyacetic acid (AOAA) in preparation of a drug or health-care product for preventing or treating myocardial infarction. The AOAA can improve cardiac functions after myocardial infarction and reduce myocardial infarction areas so as to prevent or treat the myocardial infarction.

Description

technical field [0001] The invention belongs to the pharmaceutical technology, and specifically relates to the application of aminooxyacetic acid in the preparation of medicines for preventing or treating acute myocardial infarction. Background technique [0002] Myocardial infarction is a cardiovascular disease that seriously endangers human health. With the continuous improvement of people's living standards in our country, the incidence of ischemic myocardial infarction is also increasing. An ischemic myocardial infarction can lead to scarring that can affect heart function. Most of the current drug or device treatments can only relieve the symptoms, but they cannot reverse the damage to the heart tissue. Although heart transplantation can completely improve the state of the heart, it is difficult to be widely used clinically due to factors such as scarcity of donor sources, immune rejection, and expensive treatment costs. At present, there are research reports on the a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/195A61P9/10
CPCA61K31/195A61P9/10
Inventor 陈维倩周文静赵培沈振亚惠杰
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com